Adaptive Immune Cell Engagers

The destruction of foreign or abnormally altered cells by T cells is a core component of immune defense, but some tumor cells have developed ways to escape immune surveillance and can therefore not be attacked by T cells. Affimed’s T cell engagers are designed to unmask the tumor cells and enable T cells to recognize and killed the tumor cells .

Adaptive Immune Cell Engagers Mode of Action

Redirecting T cells to fight cancer

AFM11

Targets CD19 on tumor cells and CD3 on T cells

AFM11 is a tetravalent, bispecific T cell engager that is being developed in non-Hodgkin lymphoma (NHL) and in acute lymphoblastic leukemia (ALL).

AMV564 (developed by Amphivena)

Targets CD33 on tumor cells and CD3 on T cells

AMV564 is a tetravalent, bispecific T cell engager derived from Affimed’s technology platform that is being developed by Amphivena in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay